Prof. Mimi Tang
Acting CEO, Chief Medical & Scientific Officer
Prof Tang is the inventor of the patented combination probiotic food allergen oral immunotherapy technology. She is a paediatric allergist immunologist and researcher at the Royal Children’s Hospital, Murdoch Children’s Research Institute (MCRI) and The University of Melbourne, Australia, with over 25 years clinical experience in pediatric allergy, and research experience in investigation of immunological mechanisms of allergic disease, clinical trials, and probiotic immune effects. She has authored over 350 peer reviewed journal articles, invited reviews, and book chapters, and her PhD contributed to a major shift in understanding of allergic disease (first author publication, Lancet 1994). She is actively involved in health policy and has advised government bodies including Food Standards Australia New Zealand. Prof Tang has provided consultant services to the pharmaceutical industry and sat on Industry Medical Advisory Boards and Global Scientific Advisory Committees (Immunology). She was a Board Director of the World Allergy Organisation and currently sits on expert committees of the American Academy of Allergy Asthma and Immunology (AAAAI), World Allergy Organisation (WAO), and the Australasian Society of Clinical Immunology and Allergy (ASCIA).
Director Product Development & Technical Services
Bronwyn Pollock is an experienced biotech and pharmaceutical professional with over 20 years in the industry. Prior to joining Prota as Director Product Development & Technical Services, Bronwyn was Project Manager at Neuren Pharmaceuticals Ltd, a company developing products to treat neurodegenerative diseases. She has also held Senior Management positions in pharmaceutical companies including Hospira Australia (now Pfizer), Acrux Ltd and CSL. Her CMC (Chemistry, Manufacturing and Controls) experience comes from working in R&D, quality and program management, and she has been involved in leading teams in the development and submission of numerous dossiers to EMA, US FDA, Asia and Sth America, technology transfers and launch.
Her key responsibility at Prota is to manage all facets of the drug product development through to Phase 3 clinical trials and regulatory approval.
Dr Aaron Tabensky
Director Clinical Operations & Medical Affairs
Aaron Tabensky has garnered extensive clinical development experience in the pharmaceutical industry over the past 20 years, both in Australia and abroad. Prior to joining Prota, Aaron was based in Singapore where he held positions of Director Clinical Trial Management at Abbott, Assoc. Director Global Program Manager/Regional Therapeutic Area Lead (GI) Asia Pac at Takeda, and Project Management positions at Quintiles. Before that, Aaron held clinical operations roles in Melbourne, Australia with Biogen Idec, PRA International and Servier Laboratories. His experience covers the strategic planning and functional execution of regional and global Phase 1-4 pharmaceutical clinical trials, applying project, program, CRO/vendor, budget and quality management skills and operational insights to the development and successful execution of clinical development plans, while fostering relationships with Key Opinion Leaders and other industry stakeholders. Aaron holds a PhD in the field of Osteoporosis and bone & mineral metabolism.
Aaron’s key responsibilities at Prota are to oversee the successful execution of the clinical development program.
Director Intellectual Property
Accomplished Biotech executive with over 25 years experience in a number of Australian biotech company’s including 9 years in patent attorney practice. Previous CEO of ASX listed Biotech company Dimerix Limited and current Director of a private medical foods company, Kathy brings significant strategic expertise in drug development. Kathy’s role encompasses growing the intellectual property portfolio in alignment with the company objectives.
Chief Financial Officer
Cameron is the Managing Director of bio101, a financial services firm providing outsourced CFO, accounting, tax and company secretarial services specialising in the life science sector. A qualified Chartered Accountant, Cameron acts as CFO and Company Secretary for a number of Venture Capital investee and ASX listed life science companies. In his role at bio101 Cameron has assisted clients in the IPO process and fills the role and acts as Australian Resident Director. Cameron is also a Director of registered charities Cystic Fibrosis Community Care Ltd and BioAutism Ltd.
Cameron’s key responsibility at Prota is to oversee and manage the financial function.